glp-1 palo alto Compounded GLP-1s: Why doctors worry and the FDA is cracking down The Rise of GLP-1 Medications

In the STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) for obesity, participants with baseline binge eating behaviors showed improvements in eating-related measures alongside weight loss, as assessed by questionnaires such as the Control of Eating Questionnaire

Interestingly, non-depressed individuals exposed to pro-inflammatory cytokines present with depressive-like behaviors, or sickness behaviors, characterized by anhedonia, increased pain sensitivity, and somnolence [79]

We have seen in our office patients losing anywhere from 4-12 pounds the first month, and around 20-30 pounds within 3-4 months

The role of the vagus nerve in promoting satiety appears dependent on the route of administration of GLP-1 as demonstrated in an experiment on vagotomized rats

Tirzepatide Tirzepatide is a dual agonist, meaning it acts as both a GLP-1 and GIP receptor agonist